# Steven M. Horwitz

Source: https://onco.cc/people/steven-horwitz/  
OnCo record `steven-horwitz` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led ECHELON-2, the first trial to improve survival in peripheral T-cell lymphoma, using brentuximab vedotin.

## Summary

Steven Horwitz was principal investigator of ECHELON-2, which showed brentuximab vedotin plus CHP improves progression-free and overall survival compared with CHOP in CD30-positive peripheral T-cell lymphoma, the first randomised survival benefit in the disease. He has led trials of pralatrexate, romidepsin, duvelisib and other agents in T-cell lymphomas and leads the T-cell lymphoma programme at MSKCC.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; t-cell; adc
- Role: Attending Physician, Lymphoma Service, Memorial Sloan Kettering Cancer Center
- Specialisms: Peripheral T-cell lymphoma; Cutaneous T-cell lymphoma; Antibody-drug conjugates; Novel agents

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Horwitz%20SM%5BAuthor%5D%20T-cell%20lymphoma

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [ECHELON-2](https://onco.cc/trials/echelon-2/)

---
JSON: https://onco.cc/api/v1/entities/steven-horwitz.json